INTRODUCTION
The epidemiology of infection with Toxoplasma gondii has changed in Sweden since the 1950s. The seroprevalence in pregnant women has decreased in the Stockholm area from around 50 % to 14 % [1, 2] , same thing is also reported from other parts of Europe [3] [4] [5] [6] [7] . Within Sweden, the prevalence of infection decreases with latitude, ranging from 26 % in the south of Sweden, similar to Denmark [8] , to 12 % in the north in 1987 [9] . Any burden of disease due to * Author for correspondence. congenital toxoplasmosis, for example neurological or visual impairment due to lesions in the brain and\or retina [10] [11] [12] is largely unknown in Sweden. The number of subsequently verified cases of congenital toxoplasmosis has been limited to single reports among the approximately 100 000 children born yearly in Sweden. However, reported cases do not represent a true indicator of the real rate as the disease is often asymptomatic. In addition, data on the risk of maternal toxoplasmosis are scanty. An incidence of 4-6\1000 pregnancies was found in a small pilot study from the southern part of Sweden 15 years ago [13] . In the Stockholm area in 1987 best estimates of between 0 and 2n7 cases per 1000 pregnancies were obtained by modelling toxoplasma incidence from seroprevalence data [7] . Additionally in 1992-3, 4 seroconverters were found in 3094 pregnant women [2] .
The aim of the study was to determine the birth prevalence and risk of clinical signs, symptoms and impairment at 1 year of age due to congenital toxoplasmosis. This would inform rational decisions about preventive measures.
Studies based on women infected after the first prenatal blood sample (taken at 10-12 weeks of gestation) have shown that neonatal detection of IgM on blood spots is 70-80 % sensitive [14] . However, sensitivity may be lower for babies born to women infected in the first trimester of pregnancy. We therefore also attempted to identify all women who were possibly infected during pregnancy, in addition to identifying children by neonatal screening. We followed up all children to determine congenital infection status.
POPULATION AND METHODS
After delivery, all mothers of children born in Stockholm County between 1 April 1997 and 31 July 1998 and in Ska/ ne County between 1 May 1997 and 31 July 1998 received written information about the study and consent to participation was sought. If the mother declined this was marked on the phenylketonuria card, (PKU card). Blood spots were collected on filter paper cards between days 3-5 after birth, as part of the routine screening for inborn error of metabolism (e.g. phenylketonuria) and congenital hypothyroidism.
Screening for mothers infected during pregnancy and follow up of their children
Mothers with previous toxoplasma infection were identified by analysis of the eluates from blood spots on PKU cards for toxoplasma IgG antibody activity.
To identify women infected during pregnancy, stored prepartum samples obtained in week 12 (mean, SD 4n61 weeks) from the seropositive mothers were tested for specific IgG and IgM.
The following definitions were used : (a) definitive infection, seroconversion -a change from undetectable anti-toxoplasma IgG antibodies in the sample drawn during early pregnancy to detectable IgG antibodies after birth ; (b) possibly infected ; IgG level 100 IU or demonstrable IgM and an IgG avidity index 30.
To confirm serological results, women possibly infected during pregnancy and their children were sampled for confirmatory serological analyses (specific IgM\A and IgG tests)
All children born to women who were possibly infected during pregnancy were followed clinically and serologically for 12 months.
Clinical, neurological and ophthalmological assessments and evaluation of developmental milestones were performed at 1, 3, 6, 9, and 12 months. A cranial ultrasound investigation was performed at the first visit and, in children with confirmed congenital toxoplasmosis, computerized tomography of the brain was also performed. A psychometric evaluation using the Griffith developmental scale [15] was performed between 12 and 15 months of age.
The ophthalmological investigations depended on the age of the patients and included external investigation of major ocular malformations, visual acuity assessment with the preferential looking technique, evaluation of ocular motility, cover for the detection of strabismus, evaluation of pupillary reactions to light and indirect ophthalmology monocularly and\or binocularly for the detection of signs of chorioretinitis in the fundi. A hearing assessment was routinely performed at the health care centre at 8 months of age.
Antibody levels were measured between 3 weeks and 3 months, and repeated at 3, 6, 9 and 12 months of age.
The criteria for serodiagnosis of possible toxoplasma infection during pregnancy were based on the definitions of a European Union Concerted Action on Congenital Toxoplasmosis [16] modified by the addition of avidity test [17, 18] . To certify correct identity of samples from the mothers and to exclude other potential hazardous infections, pregnancy sera were tested in parallel against TORCH (toxoplasma, rubella, CMV, herpes simplex virus type common and type 2) antigens.
Neonatal screening
Infected children were identified by detection of toxoplasma IgM in eluates from PKU-cards. If IgM was positive further serum samples were taken from the child and mother for confirmatory analyses of IgM\IgA. Children with serological markers for toxoplasma infection were followed clinically and serologically to 12 months of age in the same way as the children born to possibly infected mothers.
The criterion for diagnosis of congenital toxoplasmosis was the presence of specific IgG at 12 months of age.
Laboratory assays
Eluates from PKU filter paper cards (Schleicher & Schull no 903, Dassel, Germany) : disks were cut out from the PKU cards (diameter 3n2 mm) and analysed for specific IgM antibodies (FEIA, Labsystem, Helsinki) as described [19] and for specific IgG antibodies [20] (EIA, Labsystem, Helsinki).
Maternal sera were analysed for specific antibodies using an automated ELISA (Toxo IgM, Toxo IgG, Abbotts Diagnostics). Sera from the children were analysed for specific IgM and IgG using the same assays and for specific IgM and IgA also ISAGA PLUS IgA\IgM test (Bio-Merieux). Avidity of the IgG antibodies was measured using a commercial assay (Labsystem, Helsinki). The interpretation of the avidity results was according to the manufacturer recommendations : index 30 % excludes a primary infection within 3 months ; an index 15 % is compatible with an acute infection ; 15-30 % is an intermediate value that may indicate primary infection during the last 6 months.
PCR for detection of Toxoplasma gondii DNA, using a nested technique, was performed in all children born to women with suspected infection during pregnancy using EDTA-blood from the newborn. The DNA was prepared from leucocyte suspension, containing approximately 500 µl lysed EDTA-blood, with the Qiagen Amp Kit (Qiagen, Stockholm, Sweden) and eluted in 100 µl H # O. 20 µl of the purified DNA were then T. gondii B1 gene amplified with a nested PCR method [21] slightly modified from Burg [22] . The nested PCR fragments were separated by ethidium bromide stained agarose gel (4 %) electrophoresis and compared to a standard DNA molecular size ladder (100 bp).
The diagnosis of congenital toxoplasmosis was finally established at 12 months of age if the child still had specific IgG antibodies.
This study was approved by the ethical committee at the Karolinska Institutet.
RESULTS
Eluates from 40978 new-borns were analysed ; 26885 were from the Stockholm area (65n6 %) and 14093 from Ska/ ne (34n4 %), representing 97n1 % of all newborns during the study period.
Screening for mothers infected during pregnancy and follow up of their children
Specific IgG was found in 3772 cards in Stockholm and 3618 cards in Ska/ ne, giving a seroprevalence of 14n0 % in the Stockholm area and 25n7 % in Ska/ ne. The results are shown in detail in Figure 1 .
In total, 7390 pregnancy sera were requested of mothers with IgG positive children. Of these 30 % could not be retrieved due to a health service reorganisation in Ska/ ne. Thus 33589 women were susceptible to toxoplasma infection (i.e. specific IgG negative).
Seroconversion was detected in 12 women. At follow up 3 of the 12 children born to these women had evidence of congenital infection based on specific IgM and IgA antibodies in confirmatory neonatal serum and persistence of IgG at the age of 12 months.
IgG seroconversion but no other serological markers for toxoplasma infection was found in a further six mothers. These sera were, however, not considered further as the antibody profiles in TORCH analysis indicated they had been mislabelled. Children of these six mothers were anyway followed to 12 months but none had any clinical or serological evidence of congenital infection.
The incidence of primary infection with Toxoplasma gondii (defined as seroconversion during pregnancy in women giving birth to live children) was 0n51 per 1000 susceptible pregnancies (9 months) (95 %CI l 0n26-0n89 ; based on the Poisson distribution). The overall risk of mother to child transmission was 3\12 l 25 %.
Another 31 children were enrolled in the follow-up study due to suspicion of infection between conception and the first prenatal sample. Of these 3 were lost to follow-up either due to parental refusal (1), refusal of paediatrician (1) or emigration (1) . None of the children lost to follow-up had demonstrable IgM antibodies in the PKU card eluates or clinical signs of toxoplasma infection. All 28 children followed for 12 months became seronegative, thus excluding a congenital infection. 
Neonatal screening
Fourteen children were IgM positive on PKU card screening (Fig. 2) . Three of these had congenital infection confirmed at 1 year, and one preterm child died without clinical signs or post mortem findings of congenital toxoplasmosis. In the remaining 10 children the diagnosis of congenital toxoplasmosis was excluded. In 8 of these 10 children neonatal investigation including serum sampling from the child and the mother was required. Confirmatory analyses were negative and further follow up was not indicated. Due to high levels of IgG antibodies in the newborn and the mother, two children were followed until 1 year of age but were not treated.
All three children with congenital toxoplasmosis were born to mothers who had seroconverted during pregnancy and who were identified by the retrospective testing of stored prenatal samples. They were born in gestational week 39 or 40 and received treatment for 1 year [23] . Two of these children had clinical signs of the infection : one had hydrocephalus, intracranial calcifications, a small corneal diameter and chorioretinitis in the right eye ; the other had intracranial calcifications [24] . The most severely affected child had a demonstrable toxoplasma DNA in EDTA-blood and specific IgG remained at a high level after completion of treatment.
The birth prevalence of congenital toxoplasmosis in liveborn children was 3\40978 equivalent to 0n73\ 10 000 (95 % CI 0n15-2n14).
DISCUSSION
The prevalence of susceptibility to toxoplasma infection in pregnant women was higher than reported in 1982-3. In the southern part of Sweden (Ska/ ne) the seroprevalence fell from 40 % to 25n7 % and is now Screening for congenital toxoplasmosis very similar to neighbouring Denmark (27n6 %) [14] . As previously reported, the prevalence of seropositivity to toxoplasma infection decreased with latitude, being 14n0 % in the Stockholm area. The incidence of infection in susceptible women was 0n51\1000 (95 % CI 0n35-1n18) calculated as seroconversions per 1000 pregnancies in susceptible women. Comparison of this figure with other countries is difficult as few studies take account of the time period between the negative and positive test when reporting incidence [6] . Recent estimates of the incidence\1000 susceptible pregnancies are 2n9 (2n48-3n45) in Denmark [14] , 0n82 (0n48-1n32) in Norway (based on 11 seroconversions) [25] , and 3n4 (2n23-4n86) in Finland [26] . The incidence is similar for Sweden and Norway but significantly higher in Finland and Denmark. These differences may reflect the use of different tests and different cut-offs for test positivity, or genuine regional differences in exposure.
The birth prevalence of congenital toxoplasmosis in this Swedish study is 0n73\10 000 but with wide confidence intervals (95 % CI 0n15-2n14). The birth prevalence of congenital toxoplasmosis per 10 000 live births reported elsewhere in Scandinavia is 3n0 (95 % CI 1n98-4n37) in Denmark [14] , 3n3 in Norway (95 % CI 1n63-5n83) [25] , and 2n4 (95 % CI 0n7-6n1) in Finland [26] . Although all these studies were performed during a reasonably close time period (Denmark 1992-6, Norway 1992-4, Finland 1988-9), there is a significant difference between the birth prevalence observed in Sweden compared with Denmark (P l 0n01) and Norway (P l 0n15) but not Finland (P l 0n11) (2 sided Fisher's exact test). There may truly be a lower prevalence in Sweden possibly due to different dietary habits and\or latitude. A similar figure to Sweden was reported from New England. This was 0n82\10 000 births (95 % CI ; 0n61-1n07) [27] . Conversely, a recent report from Poznan (Polen), gave a birth prevalence of 4n72\10 000 births (2n51-8n08) [28] .
False positive results in screening tests results add to the anxiety of parents and to costs and the requirements for specificity are very high. In the present investigation, a setting of a study, the positive predictive value of screening for seroconversion was 6 % (12\210 see Fig. 1 ). In other words, for every 100 women requiring further testing, only 6 truly seroconverted. This figure underestimates the number unnecessarily requiring further testing as we did not undertake retrospective testing of stored samples in mother-child pairs with undetectable IgG on the PKU card. The positive predictive value of a positive neonatal IgM result on PKU card (Fig. 2) was reasonable (3\14, 21 %). In our study 11 false positive reactions occurred (0n25\1000). In the majority of cases, serological follow up of the mother and child resolved the diagnostic situation, minimizing the need for unnecessary follow up of the child. Similar results for the positive predictive value of neonatal IgM screening have been reported from other programmes [14, 28] . Previous studies have found an IgM seroprevalence of 50-77 % in neonates with congenital toxoplasmosis [29, 30] . In particular, children infected early in pregnancy may have no detectable toxoplasma specific IgM at birth [29] . However, the opportunity for longer treatment of toxoplasma in pregnancy may shorten the duration of IgM response in the fetus. Few data are available on non-treated mother-child pairs. Our data adds only marginal information on the sensitivity of neonatal screening for IgM on PKU cards compared with detection of maternal infection during pregnancy and follow up of the children to 12 months. This is due to the very low prevalence of congenital toxoplasmosis : no more cases were added from the retrospective testing of prenatal samples or reported from the diagnostic laboratories. The low incidence of primary maternal infection in the Swedish pregnant population, means that the uncertain benefit of prenatal screening to a small number of women and children would not outweigh the risk of side effects from invasive diagnosis and treatment and the high cost. However, neonatal screening is clearly feasible and practical. The cost of a neonatal screening based on detection of specific IgM is low, compared to the expenses involved for caring for one severely damaged child. The number of parent falsely alerted for every true case found is minimal.
Neonatal screening has been applied for a decade in the New England area, USA [27] with a similar prevalence of congenital toxoplasmosis to Sweden and was started in 1999 in Denmark. The effectiveness of postnatal treatment in asymptomatic children is not established but is widely believed to be justified [27, 31, 32] . Our results will form the basis for consideration of a Swedish policy on neonatal screening. 
